Pearson IV, Hawe E, Zuluaga S, Scuito S, Wolowacz S, Haiderali A. Cost-effectiveness of ofatumumab plus chlorambucil in first-line chronic lymphocytic leukemia in the United Kingdom. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Hawe E, Vickers A, Mollon P, McBride D, Stull D. Secukinumab 300mg demonstrates highest probability of efficacy than other biologics in psoriasis: indirect comparison. Poster presented at the 24th European Academy of Dermatology and Venereology (EADV) Congress; October 2015. Copenhagen, Denmark. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.
Hawe E, Stull DE, McBride D, Balp MM. Improvement in quality of life (QOL) of patients with refractory chronic spontaneous/idiopathic urticaria (CSU/CIU) as assessed by the EURO-QOL (EQ-5D). Poster presented at the 23rd World Congress of Dermatology; June 2015. Vancouver, Canada.
Collins A, Hawe E, Vickers A, Mallya UG, McBride D, Capkun-Niggli G, Olson M, Thorlund K. Secukinumab 300 mg demonstrates higher probability of efficacy than other biologics in psoriasis: indirect comparison. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia.
Moloney R, Mohr P, Hawe E, Shah K, Garau M, Towse A. Payer perspectives on future acceptability of comparative effectiveness and relative effectiveness research. Int J Technol Assess Health Care. 2015 Jan;31(1-2):90-8. doi: 10.1017/S0266462315000203